STOCK TITAN

Vanguard realigns reporting; PRGO (NYSE: PRGO) shows 0 shares at parent level

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perrigo Co PLC amendment: The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned of Perrigo Co PLC common stock, representing 0% of the class.

The filing explains an internal realignment at The Vanguard Group effective January 12, 2026, under which certain subsidiaries will report ownership separately and Vanguard no longer is deemed to beneficially own securities held by those subsidiaries.

Positive

  • None.

Negative

  • None.

Insights

Amendment shows administrative reallocation of ownership reporting, not a market trade.

The amendment to the Schedule 13G states 0 shares and 0%, indicating The Vanguard Group is not reporting beneficial ownership of Perrigo Co PLC common stock at the parent level in this filing. The filing attributes the change to an internal realignment dated January 12, 2026.

Practical impact depends on subsidiary reporting; subsequent disaggregated filings may show holdings under different Vanguard entities. Cash‑flow treatment and any subsidiary amounts are not disclosed in this excerpt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does The Vanguard Group's Schedule 13G/A say about PRGO ownership?

The amended Schedule 13G reports 0 shares beneficially owned in Perrigo Co PLC, representing 0% of the class. The filing attributes this to an internal Vanguard realignment dated January 12, 2026 that changes how subsidiaries report ownership.

Does the filing indicate Vanguard sold PRGO shares?

No; the amendment attributes the reporting change to an internal realignment rather than a sale. It states Vanguard no longer is deemed to beneficially own securities held by certain subsidiaries following the January 12, 2026 realignment.

Will other Vanguard entities report PRGO holdings after the realignment?

Yes, the filing states certain Vanguard subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. Those subsidiaries may disclose holdings in separate Schedule 13 filings.

Who signed the amended Schedule 13G/A for PRGO?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026. The filing lists The Vanguard Group at 100 Vanguard Blvd., Malvern, PA as the filer address.

Does this filing change Perrigo's outstanding share count or control structure?

No; the amendment reports Vanguard's beneficial ownership status and cites internal reporting changes. It does not state any changes to Perrigo Co PLC's outstanding shares or corporate control in the provided excerpt.
Perrigo Co Plc

NYSE:PRGO

View PRGO Stock Overview

PRGO Rankings

PRGO Latest News

PRGO Latest SEC Filings

PRGO Stock Data

1.29B
137.01M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2